We utilize a multidisciplinary approach for the discovery of novel drug targets that leverages the latest advances in genetics, proteomics, and functional genomics, as well as the power of collaboration and crowdsourcing. By identifying new drug targets and developing innovative treatments, we hope to improve patient outcomes and help to address some of the world's most pressing healthcare challenges.
Our focus areas for identification of novel drug targets include:
Specificity: Novel drug targets should be specific to the disease or condition being treated, with minimal or no impact on healthy cells or tissues.
Measurable effects: Novel drug targets should have measurable effects on the underlying disease or condition, which can be assessed using relevant biomarkers or clinical endpoints.
Validated biological mechanism: Novel drug targets should be based on a sound understanding of the biological mechanism underlying the disease or condition being treated.
Accessibility: Novel drug targets should be accessible by drugs, meaning that they can be modified by small molecules or other compounds to achieve the desired therapeutic effect.
Translational potential: Novel drug targets should have translational potential, meaning that they can be translated from preclinical models to clinical trials and ultimately to the clinic.
Commercial potential: Novel drug targets should have commercial potential, meaning that they can be developed into viable products with a clear market need and potential for profitability.
Our approach to novel drug targets represents a new approach to treating a disease and offer the potential for improved efficacy and reduced side effects compared to existing treatments. The approach to disruptor drug targets offer superior efficacy, safety, or tolerability compared to other drugs within the same class.
